Domestic pharmaceutical firms mired in lackluster performance

Published: 2004-04-26 07:00:00

Updated: 2004-04-26 07:00:00

Influenced by sluggish OTC sales amid domestic business slump after implementation of SDP function in 2000, Korean pharmaceutical firms are feeling the pinch from lower growth in sales and net incomes, while foreign-invested pharmaceutical firms have enjoyed double-digit growth rates in their annual sales and net incomes, according to data released by Yakup Shinmoon.

The data, which analyzed...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.